Cancer Likelihood in Plasma
Cancer Likelihood in Plasma refers to the probability or risk assessment of the presence of cancer based on the analysis of plasma, a component of blood. This method is part of a broader category of biomarkers research, which aims to detect cancer at its earliest stages through non-invasive means. The concept hinges on identifying specific DNA, RNA, proteins, or other molecules within the plasma that are indicative of cancer.
Overview[edit | edit source]
Plasma, the liquid portion of blood, carries cells and proteins throughout the body. It is a rich source of biomarkers, including cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA), which can be shed by tumors into the bloodstream. The analysis of these biomarkers through various biotechnological techniques, such as Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR), allows for the detection of cancerous mutations and alterations.
Techniques[edit | edit source]
Next-Generation Sequencing[edit | edit source]
NGS offers a comprehensive approach to analyze the vast array of genetic information in plasma. It can identify mutations, copy number variations, and other genetic alterations associated with cancer.
Polymerase Chain Reaction[edit | edit source]
PCR is a more targeted approach, used to amplify specific DNA sequences known to be associated with cancer. It is highly sensitive and can detect low levels of ctDNA in the plasma.
Applications[edit | edit source]
The primary application of assessing cancer likelihood in plasma is in the early detection and monitoring of cancer. It can be used to:
- Screen for early-stage cancers in asymptomatic individuals.
- Monitor treatment response and detect recurrence in cancer patients.
- Guide treatment decisions by identifying targetable mutations.
Challenges and Future Directions[edit | edit source]
While the potential of plasma-based biomarkers in cancer detection is significant, there are challenges to its widespread implementation, including the need for high sensitivity and specificity, standardization of techniques, and cost-effectiveness. Ongoing research and technological advancements are expected to address these challenges, making plasma-based cancer detection a more integral part of personalized medicine and cancer care.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
